APPLICATION
ANDA203146
TYPE
ANDA
ORIGINAL APPROVAL
2014-09-19
LATEST ACTION
2023-06-07
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING
MARKETING STATUS
Prescription
Products
RIZATRIPTAN BENZOATEPrescription
RIZATRIPTAN BENZOATE EQ 5MG BASE · TABLET, ORALLY DISINTEGRATING · ORAL
RIZATRIPTAN BENZOATEPrescription
RIZATRIPTAN BENZOATE EQ 10MG BASE · TABLET, ORALLY DISINTEGRATING · ORAL
Approval history
2023-06-07Labeling · Supplement 22 · standardAP
2019-11-29Labeling · Supplement 17 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.